Akebia Therapeutics (AKBA) Getting Somewhat Favorable Press Coverage, Report Finds

Media stories about Akebia Therapeutics (NASDAQ:AKBA) have been trending somewhat positive on Friday, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Akebia Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.6766821776914 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

AKBA has been the subject of a number of research reports. Piper Jaffray Companies initiated coverage on shares of Akebia Therapeutics in a research note on Monday, December 18th. They issued an “overweight” rating and a $26.00 price target for the company. BTIG Research initiated coverage on shares of Akebia Therapeutics in a research note on Thursday, December 7th. They issued a “buy” rating and a $30.00 price target for the company. Royal Bank of Canada reissued a “hold” rating and issued a $17.00 price target on shares of Akebia Therapeutics in a research note on Thursday, November 2nd. HC Wainwright reissued a “buy” rating and issued a $24.00 price target on shares of Akebia Therapeutics in a research note on Wednesday, November 15th. Finally, Mizuho reissued a “buy” rating and issued a $24.00 price target on shares of Akebia Therapeutics in a research note on Thursday, November 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $22.20.

Akebia Therapeutics (NASDAQ AKBA) opened at $15.58 on Friday. Akebia Therapeutics has a one year low of $8.58 and a one year high of $20.25. The firm has a market cap of $736.45, a P/E ratio of -4.93 and a beta of 0.87.

Akebia Therapeutics (NASDAQ:AKBA) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.07. Akebia Therapeutics had a negative net margin of 137.80% and a negative return on equity of 198.85%. The business had revenue of $41.28 million during the quarter, compared to the consensus estimate of $34.00 million. equities analysts predict that Akebia Therapeutics will post -2.25 earnings per share for the current fiscal year.

WARNING: “Akebia Therapeutics (AKBA) Getting Somewhat Favorable Press Coverage, Report Finds” was reported by Week Herald and is owned by of Week Herald. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://weekherald.com/2018/01/12/akebia-therapeutics-akba-getting-somewhat-favorable-press-coverage-report-finds.html.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Insider Buying and Selling by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply